The Efficacy and Safety of GLP-1RA Combined with SGLT2i in the Treat-ment of Overweight/Obese T2DM Patients
Objective Exploring the efficacy and safety of glucagon-like peptide-1 receptor agonist(GLP-1RA)com-bined with sodium-glucose transporter 2 inhibitors(SGLT2i)in the treatment of overweight/obese type 2 diabetes mel-litus(T2DM)patients.Methods A total of sixty-two overweight/obese T2DM patients admitted to the Second People's Hospital of Zhaoqing from March 2020 to May 2022 were non-randomly selected as the research objects and divided into two groups according to different treatment methods,with thirty-one cases in each group.The control group was treated with SGLT2i,and the study group was treated with GLP-1 RA combined with SGLT2i.Compared the two groups of blood glucose index,body mass index,treatment effect,and the occurrence of adverse reactions.Results The blood glucose index,body mass index,therapeutic effect and adverse reactions were compared between the two groups.The blood glucose level and BMI in the study group were lower than those in the control group,and the differ-ences were statistically significant(both P<0.05).The effective rate of treatment in the study group was 96.8%(30/31),which was better than 77.4%(24/31)in the control group,and the difference was statistically significant(χ2=4.897,P<0.05).There was no significant difference in the total incidence of adverse reactions between the study group and the control group(P>0.05).Conclusion The application of GLP-1RA combined with SGLT2i in the treatment of over-weight/obese T2DM patients can greatly reduce the body's blood glucose level and body mass index,without increas-ing adverse reactions and therapeutic effects.
NETL
NSTL
万方数据
